Effect of weight loss methods on lifespan in metabolic syndrome patients
Effectiveness of Pharmacologic, Surgical, and Dietetic Weight Loss Methods on Lifespan in Patients With Metabolic Syndrome: a Comparative Clinical Trial
This study is testing different weight loss methods to see how they affect the health and lifespan of adults with metabolic syndrome, type 2 diabetes, and high blood pressure.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 220 (estimated) |
| Ages | 35 Years to 65 Years |
| Sex | All |
| Sponsor | University Medical Center, Kazakhstan Academic / other |
| Locations | 1 site (Astana, Astana) |
| Trial ID | NCT06410352 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of various weight loss methods, including pharmacologic, surgical, and dietary approaches, on lifespan and metabolic health in obese patients with metabolic syndrome. The study involves a 24-week open-label, multicenter design, enrolling 150 adult participants aged 35-65 with type 2 diabetes and hypertension. Participants will undergo assessments of glycemic control, lipid metabolism, quality of life, and cost-effectiveness of the interventions. The trial aims to provide comparative data on the impact of these weight loss strategies on health outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 35-65 with a diagnosis of type 2 diabetes and hypertension who are seeking weight loss solutions.
Not a fit: Patients with type 1 diabetes, severe uncontrolled hypertension, or significant cardiac disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved lifespan and quality of life for patients with metabolic syndrome through effective weight loss interventions.
How similar studies have performed: Other studies have shown promising results with weight loss interventions in metabolic syndrome, suggesting that this approach is supported by existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * written informed consent; * T2D≥3-year with glucose lowering therapy including insulin; * 35-55 years old; * BMI≥27 kg/m2 for both sex, for Asian ethnicity; * ongoing treatment with antihypertensive treatment; * weight loss 15-20% at baseline and dynamic follow-up up to 24 weeks. Exclusion Criteria: * T1D; * \<34 age \>56 years old; * unstable cardiac disorders (New York Heart Association class IV heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart disease, or severe uncontrolled hypertension); * glomerular filtration rate \<30 mL/min and/or dialysis within 14 days before screening; • malignancy within the past 5 years; * gestation or lactation; * hereditary diseases; * known hypersensitivity to any of the test substances.
Where this trial is running
Astana, Astana
- Kuat Pernekulovich Oshakbayev — Astana, Astana, Kazakhstan (Recruiting)
Study contacts
- Principal investigator: Kuat Oshakbayev, professor — University Medical Center, Kazakhstan
- Study coordinator: full-professor Kuat Oshakbayev
- Email: okp.kuat@gmail.com
- Phone: +77013999394
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.